KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Assets (2016 - 2025)

Historic Current Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $4.1 billion.

  • Alnylam Pharmaceuticals' Current Assets rose 2292.3% to $4.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.1 billion, marking a year-over-year increase of 2292.3%. This contributed to the annual value of $4.1 billion for FY2025, which is 2292.3% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Current Assets stood at $4.1 billion for Q4 2025, which was up 2292.3% from $4.0 billion recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Current Assets' 5-year high stood at $4.1 billion during Q4 2025, with a 5-year trough of $2.5 billion in Q1 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Current Assets averaged around $3.0 billion, with its median value being $2.9 billion (2021).
  • Its Current Assets has fluctuated over the past 5 years, first soared by 5586.35% in 2021, then tumbled by 930.31% in 2022.
  • Alnylam Pharmaceuticals' Current Assets (Quarter) stood at $2.8 billion in 2021, then dropped by 4.14% to $2.7 billion in 2022, then grew by 10.79% to $3.0 billion in 2023, then grew by 10.48% to $3.3 billion in 2024, then grew by 22.92% to $4.1 billion in 2025.
  • Its last three reported values are $4.1 billion in Q4 2025, $4.0 billion for Q3 2025, and $3.6 billion during Q2 2025.